Seeking Alpha
11 Nov 2025, 15:00 UTC · 45w ago
Verdict
Headline takes no side. We score GMED +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 94% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Globus Medical increased its full-year adjusted earnings guidance to $3.80 per share.
More positive than 99% of claims this week
The company reported 7% organic growth in Q3 results.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
Globus Medical is successfully integrating acquisitions including NuVasive and Nevro.
So whatSuccessful M&A integration reduces execution risk and unlocks synergy-driven margins.
More positive than 76% of claims this week
The company's shares are trading at 21x earnings.
So whatA reasonable valuation multiple suggests there is room for further growth without being overextended.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
Strong Q3 results, organic growth, and an increase in full-year earnings guidance.
More positive than 59% of ticker scores this week
Mentioned as a successful acquisition contributing to Globus Medical's rebound.
More positive than 59% of ticker scores this week
Mentioned as a successful acquisition contributing to Globus Medical's rebound.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 96% of relationship scores this week
[a_to_b] Globus Medical has acquired Nevro.
−13.1%
Price is moving against the score
$75.05 vs $86.36 close before publication (Nov 10) · not market-adjusted
GMED chart →